Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia.
This article examines the diversity and biologic role of human lymphocyte antigen (HLA) genes as related to marrow transplantation for chronic myelogenous leukemia (CML). A better understanding of the nature and function of HLA variation is necessary as unrelated marrow transplantation evolves into a safe and effective treatment for CML. HLA matching is an important aspect of donor selection criteria and has a role in engraftment as well as the development of graft-versus-host disease and tolerance after transplant.
Petersdorf
E
E
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Anasetti
C
C
Servida
P
P
Martin
P
P
Hansen
J
J
D016026:Bone Marrow Transplantation; D006084:Graft Rejection / Q000235:genetics; D006086:Graft vs Host Disease / Q000235:genetics*; D006680:HLA Antigens / Q000235:genetics*; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D014019:Tissue Donors; D016896:Treatment Outcome
D006680:HLA Antigens